Linezolid · Regulatory label update

FDA supplemental approval: Linezolid (Labeling)

U.S. Food and Drug Administration · July 28, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

This is an FDA supplemental approval for a labeling change to linezolid 600 mg tablet (generic product by Zydus Pharms). The record documents the regulatory action and approval date but does not contain clinical trial results, efficacy data, or safety findings.

What was studied

Regulatory label update.

Key findings

Safety

No safety or adverse event data are provided.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

FDA supplemental approval for linezolid labeling change; this is a regulatory action, not a clinical trial, and does not report efficacy or safety data.

Reported figures

Quoted from the source exactly as published.

Approval status date2026-07-28

Linezolid formulationTABLET, ORAL, 600 MG

Caveats

This record is a regulatory action only and does not contain clinical trial results, efficacy data, or comparative outcomes.
The specific labeling changes approved are not detailed in this record.
No safety or adverse event data are provided.
No information on the clinical rationale for the labeling supplement is included.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record; no study design applicable.

Directness

insufficient

Labeling approval record; clinical outcomes not reported.

Consistency

insufficient

Single regulatory action; no comparative or replicative data presented.

Risk of bias

insufficient

Regulatory record does not describe trial methodology or bias assessment.

Sample adequacy

insufficient

No study population or sample size reported in this approval record.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Drugs@FDA record for application ANDA206097. This is a regulatory action record, not a clinical study. Brand name: LINEZOLID. Active ingredient: LINEZOLID. Sponsor: ZYDUS PHARMS. Submission type: SUPPL (supplement). Submission class: Labeling. Approval status date: 2026-07-28. Products: LINEZOLID, TABLET, ORAL, LINEZOLID 600MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Zydus PharmsLinezolid